Bone Directed Therapies for Prostate Cancer

Journal of Urology

Volumn 178, Issue 3 SUPPL., 2007, Pages

  Bradley, Deborah A ^a   Hussain, Maha ^a   DiPaola, Robert S ^b   Kantoff, Philip ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

bone and bones; neoplasm metastasis; prostate; prostatic neoplasms

Indexed keywords

ANDROGEN; ATRASENTAN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CILENGITIDE; CLODRONIC ACID; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; INTEGRIN; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RADIOPHARMACEUTICAL AGENT; REBIMASTAT; SAMARIUM; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; STRONTIUM; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE NECROSIS; BONE REMODELING; BONE TURNOVER; CANCER CELL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HEMATOLOGIC DISEASE; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; JAW DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOBLAST; OSTEOCLAST; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; TARGET CELL; TREATMENT OUTCOME;

BONE NEOPLASMS; HUMANS; MALE; OSTEOCLASTS; PROSTATIC NEOPLASMS;

EID: 34547672621     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.04.035     Document Type: Article

References (71)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43
2. Tannock I.F., deWit R., Berry W.R., Horti J., Pluzanska A., and Chi K.N. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
3. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.H., Jones J.A., and Taplin M.E. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
4. Chirgwin J.M., Mohammad K.S., and Guise T.A. Tumor-bone cellular interactions in skeletal metastases. J Musculoskeletal Neuronal Interact 4 (2004) 308
5. Keller E.T., and Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91 (2004) 718
6. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 1655
7. Wada T., Nakashima T., Hiroshi N., and Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12 (2006) 17
8. Mundy G.R. Endothelin-1 and osteoblastic metastasis. Proc Natl Acad Sci U S A 100 (2003) 10588
9. Lynch C.C., Hikosaka A., Acuff H.B., Martin M.D., Kawai N., and Singh R.K. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 7 (2005) 485
10. Saad F. Bone-directed treatments for prostate cancer. Hematol Oncol Clin North Am 20 (2006) 947
11. Martin T.J. Paracrine regulation of osteoclast formation and activity: milestones in discovery. J Musculoskelet Neuronal Interact 4 (2004) 243
12. Berruti A., Piovesan A., Torta M., Raucci C.A., Gorzegno G., and Paccotti P. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension. Br J Cancer 73 (1996) 1581
13. Vinholes J., Coleman R., and Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 22 (1996) 289
14. Percival R.C., Urwin G.H., Harris S., Yates A.J., Williams J.L., and Beneton M. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 13 (1987) 419
15. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., and Strayhorn C. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107 (2001) 1235
16. Carlin B.I., and Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88 suppl (2000) 2989
17. Karsenty G. Bone formation and factors affecting this process. Matrix Biol 19 (2000) 85
18. Parfitt A.M. The mechanism of coupling: a role for the vasculature. Bone 26 (2000) 319
19. Boyce B.F., Hughes D.E., Wright K.R., Xing L., and Dai A. Recent advances in bone biology provide insight into the pathogenesis of bone diseases. Lab Invest 79 (1999) 83
20. Kostenuik P.J. Revisiting the seed and soil theory of bone metastasis: new tools, same answer. J Musculoskelet Neuronal Interact 4 (2004) 375
21. Franceschi R.T. The developmental control of osteoblast-specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit Rev Oral Biol Med 10 (1999) 40
22. Saad F., Clarke N., and Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 49 (2006) 429
23. Michaelson M.D., and Smith M.R. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23 (2005) 8219
24. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., and Lacombe L. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458
25. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., and Lacombe L. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879
26. Ryan C.W., Huo D., Demers L.M., Beer T.M., and Lacerna L.V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176 (2006) 972
27. Michaelson M.D., Kaufman D.S., Lee H., McGovern F.J., Kantoff P.W., and Fallon M.A. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 25 (2007) 1038
28. Mason M.D., and Collaborators M.P. Development of bone metastases from prostate cancer: first results of the MRC PR04 trial (ISCRTN 61384873). J Clin Oncol 22 (2004) 4511
29. Smith M.R., Kabbinavar F., Saad F., Hussain A., Gittelman M.C., and Bilhartz D.L. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 2918
30. Brubaker K.D., Brown L.G., Vessella R.L., and Corey E. Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer 6 (2006) 15
31. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 (2006) 508
32. Saad F., Higano C.S., Sartor O., Colombel M., Murray R., and Mason M.D. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 4 (2006) 257
33. Goblirsch M., Lynch C., Mathews W., Manivel J.C., Mantyh P.W., Clohisy D.R., et al. Radiation treatment decreases bone cancer pain, osteolysis and tumor size. Radiat Res 161 (2004) 228
34. Porter A.T., McEwan A.J., Powe J.E., Reid R., McGowan D.G., and Lukka H. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25 (1993) 805
35. Sartor O., Reid R.H., Hoskin P.J., Quick D.P., Ell P.J., and Coleman R.E. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63 (2004) 940
36. Tu S.M., Millikan R.E., Mengistu B., Delpassand E.S., Amato R.J., and Pagliaro L.C. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (2001) 336
37. Tu S.M., Kim J., Pagliaro L.C., Vakar-Lopez F., Wong F.C., and Wen S. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol 23 (2005) 7904
38. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., and Moffett A.H. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821
39. Hamdy N.A. Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep 8 (2006) 50
40. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., and Shekarriz B. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94 (2002) 17
41. Lara Jr. P.N., Stadler W.M., Longmate J., Quinn D.I., Wexler J., and VanLoan M. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12 (2006) 1556
42. Shakespeare W.C., Metcalf III C.A., Wang Y., Sundaramoorthi R., Keenan T., and Weigele M. Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 6 (2003) 729
43. Metcalf III C.A., vanSchravendijk M.R., Dalgarno D.C., and Sawyer T.K. Targeting protein kinases for bone disease: discovery and development of Src inhibitors. Curr Pharm Des 8 (2002) 2049
44. Shakespeare W., Yang M., Bohacek R., Cerasoli F., Stebbins K., and Sundaramoorthi R. Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A 97 (2000) 9373
45. Pidgeon G.P., Tang K., Cai Y.L., Piasentin E., and Honn K.V. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v) beta(3) and alpha(v) beta(5) integrin expression. Cancer Res 63 (2003) 4258
46. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., and Klier G. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79 (1994) 1157
47. Teitelbaum S.L. Osteoclasts and integrins. Ann N Y Acad Sci 1068 (2006) 95
48. Dresner-Pollak R., and Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J Cell Biochem 56 (1994) 323
49. Beekman K.W., Colevas A.D., Cooney K., Dipaola R., Dunn R.L., and Gross M. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 4 (2006) 299
50. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., and Eisenberger M.A. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1 (1995) 944
51. Yin J.J., Mohammad K.S., Kakonen S.M., Harris S., Wu-Wong J.R., and Wessale J.L. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 100 (2003) 10954
52. Pirtskhalaishvili G., and Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 44 (2000) 77
53. Thakkar S.G., Choueiri T.K., and Garcia J.A. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep 8 (2006) 108
54. Nelson J., Bagnato A., Battistini B., and Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 3 (2003) 110
55. Gohji K., Kitazawa S., Tamada H., Katsuoka Y., and Nakajima M. Expression of endothelin receptor a associated with prostate cancer progression. J Urol 165 (2001) 1033
56. Carducci M.A., Padley R.J., Breul J., Vogelzang N.J., Zonnenberg B.A., and Daliani D.D. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21 (2003) 679
57. Vogelzang N.J., Nelson J.B., Schulman C.C., Dearnaley F., Saad F., and Sleep J.D. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23 (2005) 4563
58. Lipton A., Sleep D.J., Hulting S.M., and Isaacson J.D. Benefit of atrasentan in men with hormone refractory prostate cancer metastatic to bone. J Clin Oncol 22 (2004) 4687
59. Sleep D.J., Nelson J.B., Petrylak D.P., Isaacson J.D., and Carducci M.A. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol 24 (2006) 4630
60. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., and Smith M. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97 (2005) 59
61. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., and Smith M. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23 (2005) 4925
62. Pectasides D., Nikolaou M., Farmakis D., Kanakis I., Gaaglia A., and Kountourakis P. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res 25 (2005) 1457
63. Carducci M., Nelson J.B., Saad F., Vogelznang N.J., Zonnenberg B.A., and Daliani D.D. Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol 22 (2004) 4508
64. Moffat B.A., Chenevert T.L., Lawrence T.S., Meyer C.R., Johnson T.D., and Dong Q. Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 102 (2005) 5524
65. Hamstra D.A., Chenevert T.L., Moffat B.A., Johnson T.D., Meyer C.R., and Mukherji S.K. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A 102 (2005) 16759
66. Small E.J., Smith M.R., Seaman J.J., Petrone S., and Kowalski M.O. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21 (2003) 4277
67. Dearnaley D.P., Sydes M.R., Mason M.D., Stott M., Powell C.S., and Robinson A.C. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 95 (2003) 1300
68. Quinn J.E., Brown L.G., Zhang J., Keller E.T., Vessella R.L., and Corey E. Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis 8 (2005) 253
69. Hall C.L., and Keller E.T. The role of Wnts in bone metastases. Cancer Metastasis Rev 25 (2006) 551
70. Haudenschild D.R., Palmer S.M., Moseley T.A., You Z., and Reddi A.H. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64 (2004) 8276
71. Dai J., Keller J., Zhang J., Lu Y., Yao Z., and Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65 (2005) 8274